Skip to main content
. 2017 Nov 2;17:710. doi: 10.1186/s12885-017-3708-4

Table 2.

Patient and treatment characteristics

Variable N° (%)
Age
 Mean 65
 Rage 50–78
Sex
 Female 5 (50%)
 Male 5 (50%)
T stage
 T2 5 (50%)
 T3 5 (50%)
N stage
 N0–1 2 (20%)
 N2 6 (60%)
 N3 2 (20%)
Global stage
 II 2 (20%)
 IIIB 8 (80%)
PTV dose-tumor (Gy)
 54 Gy 10 (100%)
PTV dose-positive nodes (Gy)
 54 Gy 2 (20%)
 50.4 Gy 5 (50%)
PTV dose-elective volumes (Gy)
 45 Gy 10 (10%)

Legend: T tumor, N nodal, number, PTV planned target volume